Logo for Outlook Therapeutics Inc

Outlook Therapeutics Investor Relations Material

Latest events

Logo for Outlook Therapeutics Inc

Q3 2024

Outlook Therapeutics
Logo for Outlook Therapeutics

Q3 2024

14 Aug, 2024
Logo for Outlook Therapeutics

Q2 2024

16 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Outlook Therapeutics Inc

Access all reports
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and launching innovative treatments for ocular diseases. The company is currently working on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), aiming to make it the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The company is headquartered in Iselin, New Jersey, and its shares are listed on the Nasdaq.